 The Center is also part of the Typhoid Vaccine Acceleration Consortium (TyVAC), a collaboration between the Oxford Vaccine Group, University of Maryland School of Medicine Center for Vaccine Development.The typhoid conjugate vaccine created by TyVAC was demonstrated as a cost-effective strategy to protect people in low- and middle-income countries from typhoid.In 2018 phase 2 clinical trials began on the Influenza A virus subtype H7N9 vaccine.